Malotky M K, Pope L, Miller S D
Department of Neurobiology and Physiology, Northwestern University, Evanston, IL 60201.
J Immunol. 1994 Jul 15;153(2):841-51.
Intravenous treatment of Lewis rats with neuroantigen-coupled splenocytes 7 days before the induction of experimental autoimmune encephalomyelitis with guinea pig myelin basic protein (GP-MBP) resulted in a significant reduction of both the incidence and severity of clinical disease. To test the epitope and functional specificities of the unresponsiveness, splenocytes (SP) coupled with the major encephalitogenic MBP determinant, GP-68-86, were compared with those coupled with intact GP-MBP for the ability to down-regulate clinical disease and Ag-specific T cell responses (proliferation, cytokine production, and delayed-type hypersensitivity) in animals primed with either intact GP-MBP/CFA or GP-68-86/CFA. GP-MBP-SP and GP-68-86-SP were equally efficient at significantly inhibiting clinical disease in animals primed with GP-68-86/CFA. In contrast, tolerization with intact GP-MBP-SP was significantly more efficient than that with GP-68-86-SP at reducing disease incidence and severity in GP-MBP/CFA-primed animals, which indicates a role for secondary (cryptic) encephalitogenic epitopes in GP-MBP-induced disease. By testing a panel of GP-68-86 peptides that contained conservative amino acid substitutions at either position 75 (A75) or 80 (P80) or at both, residues that previously had been shown to be TCR contact residues, for their ability to inhibit experimental autoimmune encephalomyelitis induction, were assessed for the fine specificity of tolerance induction. None of the substituted peptides were capable of affecting the course of paralytic disease that had been induced by sensitization with the native GP-68-86 epitope, but all significantly reduced a milder form of the disease that had been produced by priming with the (A75,P80) 68-86 substituted peptide. With regard to the functional specificity of tolerance induction, lymph node T cells derived from either GP-MBP-SP- or GP-68-86-SP-treated animals exhibited a marked reduction in both proliferation and production of Th1-derived cytokines (IL-2, IFN-gamma, and lymphotoxin/TNF-alpha) in response to either GP-MBP or GP-68-86 in culture. In contrast, no consistent significant differences in delayed-type hypersensitivity responses were observed in any of the experimental groups relative to controls. Histologic examination of central nervous system tissues from the tolerant and control groups revealed significantly reduced, but still demonstrable, levels of perivascular infiltration even in asymptomatic animals.
在用豚鼠髓鞘碱性蛋白(GP-MBP)诱导实验性自身免疫性脑脊髓炎前7天,对Lewis大鼠进行神经抗原偶联脾细胞的静脉注射治疗,可使临床疾病的发病率和严重程度显著降低。为了测试无反应性的表位和功能特异性,将与主要致脑炎性MBP决定簇GP-68-86偶联的脾细胞(SP)与与完整GP-MBP偶联的脾细胞在下调临床疾病和Ag特异性T细胞反应(增殖、细胞因子产生和迟发型超敏反应)方面的能力进行比较,这些反应发生在用完整GP-MBP/CFA或GP-68-86/CFA致敏的动物中。GP-MBP-SP和GP-68-86-SP在显著抑制用GP-68-86/CFA致敏的动物的临床疾病方面同样有效。相比之下,在用GP-MBP/CFA致敏的动物中,用完整GP-MBP-SP诱导耐受在降低疾病发病率和严重程度方面比用GP-68-86-SP显著更有效,这表明二级(隐蔽)致脑炎性表位在GP-MBP诱导的疾病中起作用。通过测试一组在第75位(A75)或第80位(P80)或两者都含有保守氨基酸替代的GP-68-86肽段(这些残基先前已被证明是TCR接触残基)抑制实验性自身免疫性脑脊髓炎诱导的能力,评估耐受诱导的精细特异性。没有一种替代肽能够影响用天然GP-68-86表位致敏所诱导的麻痹性疾病的进程,但所有替代肽都显著减轻了用(A75,P80)68-86替代肽致敏所产生的较轻形式的疾病。关于耐受诱导的功能特异性,来自用GP-MBP-SP或GP-68-86-SP处理的动物的淋巴结T细胞在培养中对GP-MBP或GP-68-86的反应中,增殖和Th1衍生细胞因子(IL-2、IFN-γ和淋巴毒素/TNF-α)的产生均显著降低。相比之下,相对于对照组,在任何实验组中均未观察到迟发型超敏反应的一致显著差异。对耐受组和对照组中枢神经系统组织的组织学检查显示,即使在无症状动物中,血管周围浸润水平也显著降低,但仍可检测到。